NASDAQ: GCTKGlucotrack Inc Stock Ownership - Who owns Glucotrack?
Insider buying vs selling
Have Glucotrack Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| John Ballantyne | Director | 2024-11-14 | 132,036 | $31.00 | $4.09MBuy |
| Erin Catherine Carter | Director | 2024-11-14 | 2,078 | $31.20 | $64.83kBuy |
| Paul Goode | Chief Executive Officer | 2024-11-14 | 796 | $31.20 | $24.84kBuy |
| A. Ballantyne Revocable Living Trust Dated 08 John | 10% Owner | 2024-11-14 | 132,036 | $31.00 | $4.09MBuy |
| Luis Malave | Director | 2024-11-14 | 6,886 | $31.20 | $214.84kBuy |
GCTK insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when GCTK insiders and whales buy or sell their stock.
GCTK Shareholders
What type of owners hold Glucotrack Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| John Ballantyne | 418.91% | 3,767,750 | $24.38M | Insider |
| Drew Sycoff | 328.13% | 2,951,257 | $19.09M | Insider |
| A. Ballantyne Revocable Living Trust Dated 08 John | 5.67% | 51,002 | $329.98k | Insider |
| Andrew K. Balo | 0.52% | 4,692 | $30.36k | Insider |
| Bank Of America Corp | 0.45% | 4,089 | $26.46k | Institution |
| Luis Malave | 0.45% | 4,058 | $26.26k | Insider |
| Erin Catherine Carter | 0.24% | 2,148 | $13.90k | Insider |
| Robert Fischell | 0.23% | 2,045 | $13.23k | Insider |
| Allen Danzig | 0.21% | 1,922 | $12.44k | Insider |
| Tower Research Capital LLC Trc | 0.20% | 1,772 | $11.46k | Institution |
GCTK vs Medical Stocks
Glucotrack Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.